Cargando…

Development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms

BACKGROUND: Colon neuroendocrine neoplasms (NENs) have one of the poorest median overall survival (OS) rates among all NENs. The American Joint Committee on Cancer (AJCC) tumor–node–metastasis (TNM) staging system—currently the most commonly used prediction model—has limited prediction accuracy beca...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ruitong, Zhou, Bingrong, Hu, Ping, Xue, Bingyan, Gu, Danyang, Li, Xiaolin, Tang, Qiyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349494/
https://www.ncbi.nlm.nih.gov/pubmed/34364382
http://dx.doi.org/10.1186/s12957-021-02338-8
_version_ 1783735575477485568
author Xu, Ruitong
Zhou, Bingrong
Hu, Ping
Xue, Bingyan
Gu, Danyang
Li, Xiaolin
Tang, Qiyun
author_facet Xu, Ruitong
Zhou, Bingrong
Hu, Ping
Xue, Bingyan
Gu, Danyang
Li, Xiaolin
Tang, Qiyun
author_sort Xu, Ruitong
collection PubMed
description BACKGROUND: Colon neuroendocrine neoplasms (NENs) have one of the poorest median overall survival (OS) rates among all NENs. The American Joint Committee on Cancer (AJCC) tumor–node–metastasis (TNM) staging system—currently the most commonly used prediction model—has limited prediction accuracy because it does not include parameters such as age, sex, and treatment. The aim of this study was to construct nomograms containing various clinically important parameters to predict the prognosis of patients with colon NENs more accurately. METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, we performed a retrospective analysis of colon NENs diagnosed from 1975 to 2016. Data were collected from 1196 patients; almost half were female (617/1196, 51.6%), and the average age was 61.94 ± 13.05 years. Based on the age triple cut-off values, there were 396 (33.1%), 408 (34.1%), and 392 (32.8%) patients in age groups 0–55 years, 55–67 years, and ≥ 68 years, respectively. Patients were randomized into training and validation cohorts (3:1). Independent prognostic factors were used for construction of nomograms to precisely predict OS and cancer-specific survival (CSS) in patients with colon NENs. RESULTS: Multivariate analysis showed that age ≥ 68 years, sex, tumor size, grade, chemotherapy, N stage, and M stage were independent predictors of OS. In the validation cohort, the Concordance index (C-index) values of the OS and CSS nomograms were 0.8345 (95% confidence interval [CI], 0.8044–0.8646) and 0.8209 (95% CI, 0.7808–0.861), respectively. C-index also indicated superior performance of both nomograms (C-index 0.8347 for OS and 0.8668 for CSS) compared with the AJCC TNM classification (C-index 0.7159 for OS and 0.7366 for CSS). CONCLUSIONS: We established and validated new nomograms for more precise prediction of OS and CSS in patients with colon NENs to facilitate individualized clinical decisions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-021-02338-8.
format Online
Article
Text
id pubmed-8349494
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83494942021-08-09 Development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms Xu, Ruitong Zhou, Bingrong Hu, Ping Xue, Bingyan Gu, Danyang Li, Xiaolin Tang, Qiyun World J Surg Oncol Research BACKGROUND: Colon neuroendocrine neoplasms (NENs) have one of the poorest median overall survival (OS) rates among all NENs. The American Joint Committee on Cancer (AJCC) tumor–node–metastasis (TNM) staging system—currently the most commonly used prediction model—has limited prediction accuracy because it does not include parameters such as age, sex, and treatment. The aim of this study was to construct nomograms containing various clinically important parameters to predict the prognosis of patients with colon NENs more accurately. METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, we performed a retrospective analysis of colon NENs diagnosed from 1975 to 2016. Data were collected from 1196 patients; almost half were female (617/1196, 51.6%), and the average age was 61.94 ± 13.05 years. Based on the age triple cut-off values, there were 396 (33.1%), 408 (34.1%), and 392 (32.8%) patients in age groups 0–55 years, 55–67 years, and ≥ 68 years, respectively. Patients were randomized into training and validation cohorts (3:1). Independent prognostic factors were used for construction of nomograms to precisely predict OS and cancer-specific survival (CSS) in patients with colon NENs. RESULTS: Multivariate analysis showed that age ≥ 68 years, sex, tumor size, grade, chemotherapy, N stage, and M stage were independent predictors of OS. In the validation cohort, the Concordance index (C-index) values of the OS and CSS nomograms were 0.8345 (95% confidence interval [CI], 0.8044–0.8646) and 0.8209 (95% CI, 0.7808–0.861), respectively. C-index also indicated superior performance of both nomograms (C-index 0.8347 for OS and 0.8668 for CSS) compared with the AJCC TNM classification (C-index 0.7159 for OS and 0.7366 for CSS). CONCLUSIONS: We established and validated new nomograms for more precise prediction of OS and CSS in patients with colon NENs to facilitate individualized clinical decisions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-021-02338-8. BioMed Central 2021-08-07 /pmc/articles/PMC8349494/ /pubmed/34364382 http://dx.doi.org/10.1186/s12957-021-02338-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Xu, Ruitong
Zhou, Bingrong
Hu, Ping
Xue, Bingyan
Gu, Danyang
Li, Xiaolin
Tang, Qiyun
Development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms
title Development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms
title_full Development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms
title_fullStr Development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms
title_full_unstemmed Development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms
title_short Development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms
title_sort development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349494/
https://www.ncbi.nlm.nih.gov/pubmed/34364382
http://dx.doi.org/10.1186/s12957-021-02338-8
work_keys_str_mv AT xuruitong developmentandvalidationofprognosticnomogramsforpatientswithcolonneuroendocrineneoplasms
AT zhoubingrong developmentandvalidationofprognosticnomogramsforpatientswithcolonneuroendocrineneoplasms
AT huping developmentandvalidationofprognosticnomogramsforpatientswithcolonneuroendocrineneoplasms
AT xuebingyan developmentandvalidationofprognosticnomogramsforpatientswithcolonneuroendocrineneoplasms
AT gudanyang developmentandvalidationofprognosticnomogramsforpatientswithcolonneuroendocrineneoplasms
AT lixiaolin developmentandvalidationofprognosticnomogramsforpatientswithcolonneuroendocrineneoplasms
AT tangqiyun developmentandvalidationofprognosticnomogramsforpatientswithcolonneuroendocrineneoplasms